Biotie Therapies Corp.
http://www.biotie.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biotie Therapies Corp.
Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug
The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
Ipsen Doubles Up In ADC Arena With Foreseen Alliance
Deal Snapshot: Ipsen has entered into a global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03bn, its second antibody-drug conjugate tie-up this year, a few months after unveiling a partnership with Sutro.
Sutro Works Toward A Better Ovarian Cancer ADC
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Elbion GmbH
- Synosia Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice